Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3919)
All Articles published online
|
Publishing Process of This Article
|
Apr 6, 2021 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Niu ZY, Sun L, Wen SP, Song ZR, Xing L, Wang Y, Li JQ, Zhang XJ, Wang FX. Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report. World J Clin Cases 2021; 9(10): 2394-2399 [PMID: 33869619 DOI: 10.12998/wjcc.v9.i10.2394] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i10/2394.htm |
| Number | Citing Articles |
| 1 |
María Antonia Pérez-Moreno, Pablo Ciudad-Gutiérrez, Didiana Jaramillo-Ruiz, Juan Luis Reguera-Ortega, Laila Abdel-kader Martín, Sandra Flores-Moreno. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review. International Journal of Molecular Sciences 2023; 24(19): 14780 doi: 10.3390/ijms241914780
|
| 2 |
Le Wang. Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Current Research in Translational Medicine 2022; 70(1): 103320 doi: 10.1016/j.retram.2021.103320
|
| 3 |
Qingzhu Jia, Aoyun Wang, Yixiao Yuan, Bo Zhu, Haixia Long. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Experimental Hematology & Oncology 2022; 11(1) doi: 10.1186/s40164-022-00277-y
|
| 4 |
|
| 5 |
Wenqi Zhang, Chen Huang, Ruixia Liu, Huichao Zhang, Weijing Li, Shaoning Yin, Lianjing Wang, Wei Liu, Lihong Liu. Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.983934
|